William Blair Reaffirms Their Buy Rating on Phasebio Pharmaceuticals (PHAS)

In a report released yesterday, Matt Phipps from William Blair reiterated a Buy rating on Phasebio Pharmaceuticals (PHASResearch Report). The company’s shares closed last Friday at $3.75.

According to TipRanks.com, Phipps is a 3-star analyst with an average return of 5.7% and a 49.4% success rate. Phipps covers the Healthcare sector, focusing on stocks such as Pieris Pharmaceuticals, Autolus Therapeutics, and Chinook Therapeutics.

Phasebio Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $13.67, representing a 243.6% upside. In a report released yesterday, Stifel Nicolaus also reiterated a Buy rating on the stock with a $8.00 price target.

See today’s analyst top recommended stocks >>

Phasebio Pharmaceuticals’ market cap is currently $190.8M and has a P/E ratio of -1.10. The company has a Price to Book ratio of 22.52.

Based on the recent corporate insider activity of 21 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PHAS in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

PhaseBio Pharmaceuticals, Inc. is engaged in the development and commercialization of biotherapeutics for the treatment of orphan diseases. It focuses on cardiopulmonary disorders. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA.